Lilly gets rare downgrade as analysts question hype over GLP-1 pills and Zepbound’s cash sales
Up next
Author


If middle-class Americans lose their jobs to AI, that could mean fewer cash sales of weight-loss drugs like Zepbound.

You May Also Like

Yen strengthens past ¥140 against dollar ahead of rate decisions

Japan’s yen has strengthened past ¥140 to the dollar for the first…
Apple reportedly ends its longtime plans to build a self-driving EV

Apple reportedly ends its longtime plans to build a self-driving EV

Apple Inc. is scrapping an ambitious, decade-long effort to develop an electric…
My late husband’s son is listed as beneficiary on his IRAs. Where does that leave me?

My late husband’s son is listed as beneficiary on his IRAs. Where does that leave me?

“My husband’s son said he doesn’t want any part of the IRAs…
The vanishing ‘Buffett premium’: Has Berkshire Hathaway lost the Oracle of Omaha’s aura?

The vanishing ‘Buffett premium’: Has Berkshire Hathaway lost the Oracle of Omaha’s aura?

The once-reliable “Buffett premium” — the idea that investors would pay extra…